Welcome to our dedicated page for CCC news (Ticker: CCC), a resource for investors and traders seeking the latest updates and insights on CCC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CCC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CCC's position in the market.
Clarivate Plc (NYSE: CLVT) has released its 2022 Journal Citation Reports (JCR), highlighting ongoing increases in citation impact for journals publishing COVID-19 research. Notably, The Lancet now holds the top Journal Impact Factor of 202.731, surpassing the New England Journal of Medicine, while Nature becomes the first journal to exceed one million citations in a year. The JCR assesses over 21,000 journals with rigorous criteria, emphasizing the profound influence of COVID-19 on academic publishing.
Clarivate Plc (NYSE:CLVT) announces the launch of a Global Research Report detailing the research landscape in eleven Central European countries. The report highlights a strong growth in research output, with these nations producing approximately 4% of global papers from 2016 to 2020, a doubling since 1990. Notably, Estonia and Latvia exhibit high international collaboration rates, reaching around 70%. The findings suggest that EU accession has positively influenced research funding and output.
Clarivate has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of drug therapeutics that can serve as medical countermeasures (MCMs) for chlorine and sulfur mustard injuries. This collaboration will utilize machine learning and artificial intelligence to identify and repurpose existing FDA-approved drugs. Funding from BARDA will facilitate target identification and analyses, aiming to provide quicker responses to chemical exposure incidents. This initiative is part of BARDA's ReDIRECT program to enhance public health preparedness.
Clarivate Plc (NYSE: CLVT) has announced an exchange offer for two series of its outstanding notes, totaling $2 billion, as part of its ongoing acquisition of ProQuest. The exchange is in response to a second request for documents from the FTC, extending the acquisition completion date to December 31, 2021. If the acquisition is not finalized by this date, the company may redeem the old notes. The new notes will mirror the old ones, with terms extending up to April 29, 2022, and will mature shortly after the old notes. The exchange offers are set to expire on August 13, 2021.
Clarivate Plc (NYSE: CCC) will report its financial results for Q1 2021 on April 29, 2021, before market opening. The press release and financial details will be available on their investor website. A conference call and webcast are scheduled for the same day at 8:00 AM ET to discuss the results. Interested parties can dial in or access the live broadcast through the company's website. An audio replay will be available two hours post-call until May 13, 2021. Clarivate provides solutions to accelerate innovation.
On January 27, 2021, Clarivate Plc (NYSE:CCC) released findings from its 2021 Global Business Survey, revealing that 33% of organizations experienced cyber attacks on their domains in 2020. Domain security is the primary concern for 56% of decision-makers surveyed. Notably, 52% spent over $25,000 on domain management last year, an increase from 39% in 2019. The report highlights a growing trend toward new generic top-level domains (gTLDs), with 53% of respondents registering them, up from 39% in 2019. Companies increasingly recognize domains as valuable assets vital for brand protection and commercial strategy.
Clarivate Plc (NYSE:CCC) has launched the Web of Science™ My Research Assistant, a mobile application designed for scientific researchers. This app enables users to search, save, and share publication records from the Web of Science citation index efficiently. It offers a free version for general users, allowing limited search functionality, while users from top research institutions gain unlimited access. The app aims to enhance the research experience by facilitating connections and delivering personalized services in a collaborative research environment.
Clarivate Plc (NYSE: CCC) announced a change of its ticker symbol to CLVT, effective February 1, 2021. This decision aims to enhance visibility among public investors and stakeholders, aligning the stock symbol with the company's name. CEO Jerre Stead highlighted the company's transformation and growth since its public listing in May 2019. Current stockholders do not need to take any action regarding this change, and the common stock will continue to trade on the NYSE with an unchanged CUSIP (G21810109).
Clarivate Plc (NYSE: CCC) has enhanced its Cortellis CMC Intelligence platform by adding comprehensive biologic CMC regulations and features. This update aims to expedite drug development, particularly vital during the COVID-19 pandemic. The platform now supports over 60 countries and helps pharmaceutical companies streamline their CMC regulatory submissions, minimizing delays and rejections due to incomplete data. Studies indicate that 50% of drugs from 2009-2012 faced rejections largely due to CMC issues, highlighting the importance of this enhancement for efficient drug approval processes.
Clarivate Plc (NYSE: CCC) has announced that Karen G. Mills, a board member, will step down to pursue other endeavors. Following her departure, the board will consist of 11 members. Executive Chairman and CEO Jerre Stead expressed gratitude for Mills' contributions since the company went public in May 2019, noting her guidance has significantly aided in the company's growth. Mills acknowledged the importance of big data and artificial intelligence in shaping Clarivate's innovative future.
